(HealthDay News) — For statin-treated patients with coronary heart disease (CHD), stabilization or improvement in renal function is associated with a reduced rate of major cardiovascular events (MACE), according to a study published in The American Journal of Cardiology.

James Shepherd, MD, from the University of Glasgow in the United Kingdom, and colleagues randomly asigned patients with CHD to atorvastatin 10 mg or 80 mg daily and followed them for 4.9 years in the Treating to New Targets (TNT) study. The researchers examined the correlation between intrastudy change in estimated glomerular filtration rate (eGFR) from baseline and the risk for MACE among 9500 patients stratified according to renal function (improving, stable, and worsening).

The researchers found that, compared with patients with worsening kidney function, a lower rate of MACE was seen for patients with stable kidney function (hazard ratio [HR]=0.72; P=.0005) and improving kidney function (HR=0.36; P<.0001). T

Continue Reading

he absolute reduction in the rate of MACE was 2.7% for each 1 mL/min/1.73² increase in eGFR. The absolute MACE rate reduction per 1 mL/min/1.73² increase in eGFR was 2.0% and 3.3% for 10 and 80 mg atorvastatin, respectively.

“In conclusion, intrastudy stabilization or increase in eGFR in atorvastatin-treated patients with CHD from the TNT study was associated with a reduced rate of [MACE],” the researchers wrote. “Statin-treated CHD patients with progressive renal impairment are at high risk for future cardiovascular events.”

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which funded the TNT study.


  1. Shepherd J, Breazna A, Deedwania PC, et al. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study). Am J Cardiol. 2016;117(8):1199-1205. doi:10.1016/j.amjcard.2016.01.014.